Cannabis Extract in Refractory Epilepsy Study

PHASE3TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 10, 2019

Primary Completion Date

March 15, 2020

Study Completion Date

March 15, 2020

Conditions
Drug Resistant Epilepsy
Interventions
DRUG

Medical Cannabis

The experimental intervention will begin with two weeks of titration (100 mg to 200 mg of CBD per day), followed by four weeks of treatment (maximum 300 mg of CBD per day) and four weeks of maintenance (maximum 300 mg of CBD per day). A two week washout phase will slowly decrease the daily dose (200 mg to 100 mg of CBD per day). All daily doses are equally divided into a morning and evening dose.

DRUG

Placebo

The placebo intervention will begin with two weeks of titration, followed by four weeks of treatment. Participants will then be unblinded to their study group and begin two weeks of titration, four weeks of treatment, and two weeks of washout with medical cannabis, following the same dosing and schedule as the experimental group. All daily doses are equally divided into a morning and evening dose.

Trial Locations (2)

Unknown

University Hospital Campus, London Health Sciences Centre, London

University Health Network - Toronto Western Hospital, Toronto

All Listed Sponsors
collaborator

Ontario Brain Institute

OTHER

collaborator

University of Toronto

OTHER

collaborator

University Health Network, Toronto

OTHER

collaborator

London Health Sciences Centre

OTHER

collaborator

MedReleaf

INDUSTRY

lead

The Epilepsy Research Program of the Ontario Brain Institute

OTHER